Monday July 16, 2018
Home Lead Story OnePlus 6 Red...

OnePlus 6 Red Edition Officially Launched For Rs 39,999 in India

The handset is powered by Qualcomm's flagship Snapdragon 845 chip and runs on OnePlus's customised version of Android "OxygenOS" which is based on Android 8.1 Oreo OS

0
//
8
OnePlus 6 Red Edition Officially Launched For Rs 39,999 in India
OnePlus 6 Red Edition Officially Launched For Rs 39,999 in India. (IANS)
Republish
Reprint

China-based smartphone manufacturer OnePlus on Monday unveiled the “red edition” of its latest flagship OnePlus 6 with 8GB RAM and 128GB internal storage for Rs 39,999.

The new variant of OnePlus 6 would be available for purchase from July 16, the company said in a statement.

“We worked to avoid an overly bright red color while still capturing a sense of self-confidence and positivity,” said Pete Lau, Founder, OnePlus.

The smartphone was launched earlier in May for Rs 34,999 for the 6GB RAM+64GB internal storage and Rs 39,999 for the 8GB RAM+128GB internal storage variant.

Also Read: OnePlus Updates ‘OnePlus Switch’ With Bug-Fixes And More

The device comes with a flagship processor, retaining the company’s proprietary “Dash Charge” that fuels the 3,300 mAh battery from zero to 100 per cent in around 80 minutes, along with a 6.28-inch AMOLED display, dual 16MP + 20MP primary camera, 16MP selfie camera and the display cutting “notch.”

The handset is powered by Qualcomm’s flagship Snapdragon 845 chip and runs on OnePlus’s customised version of Android “OxygenOS” which is based on Android 8.1 Oreo OS.

The company earlier released the “midnight black” colour variant of the smartphone late in June with 8GB RAM and 256GB internal storage priced at Rs 43,999. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)